London, 5 December 2019 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today completed submission of a New Drug Application (NDA) to the US Food and Drug…Original Article
ViiV Healthcare submits New Drug Application to the FDA for Fostemsavir, an Investigational, First-in-Class Attachment Inhibitor for the Treatment of HIV in Adults with Few Treatment Options Available
